RxDoctor Payments DataLook up a doctor →

Saad Ahmad, MD

Ophthalmology · Elmhurst, ILNPI 1881613297

Payments from drug & device makers

$63,924in general payments, 2019–2025

Across 622 payments — averaging $102.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Ocular Therapeutix, Inc.$20K
  • Alimera Sciences, Inc.$13K
  • Genentech USA, Inc.$7K
  • AbbVie$7K
  • Carl Zeiss Meditec USA, Inc.$4K
  • Astellas Pharma US Inc$2K
  • plus $10K from 27 others

What the payments were for

  • Consulting fees$9,40925%
  • Speaking & faculty fees$9,49126%
  • Travel & lodging$3,1158%
  • Food & beverage$10,64529%
  • Education$1740%
  • Other$4,23211%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$63,924 in reported general payments places this provider in the 90th percentile of 773 ophthalmology providers in Illinois.

See all ophthalmology providers in Illinois

Medicare billing

Part B allowed, 2024
$4,086,224
Medicare patients
521
Services billed
32,210

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Difluprednate818$95,404
Bromfenac Sodium288$69,458
ProlensaBromfenac Sodium145$53,383
Brinzolamide281$44,539
SimbrinzaBrinzolamide/Brimonidine Tart71$14,269
Dorzolamide Hcl489$8,435
CombiganBrimonidine Tartrate/Timolol32$7,733
RhopressaNetarsudil Mesylate16$5,830
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol56$5,365
LumiganBimatoprost11$5,149
RocklatanNetarsudil Mesylat/Latanoprost13$4,833
Prednisolone Acetate124$4,005
Gentamicin Sulfate145$998
Ketorolac Tromethamine31$934
Atropine Sulfate37$783

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa$69$53,383145 claims
AlconSimbrinza$365$14,26971 claims
AbbVieCombigan, Lumigan$6,878$12,88243 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 773 ophthalmology providers in Illinois.

Other ophthalmology in Elmhurst

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →